Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 21,300 shares, an increase of 15.1% from the October 15th total of 18,500 shares. Based on an average daily trading volume, of 16,500 shares, the short-interest ratio is presently 1.3 days. Approximately 0.2% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Akari Therapeutics in a research note on Sunday, November 10th. They set a “sell” rating on the stock.

Akari Therapeutics Price Performance

Shares of AKTX stock opened at $2.08 on Monday. Akari Therapeutics has a 1-year low of $1.08 and a 1-year high of $4.40. The firm has a fifty day moving average of $2.73 and a two-hundred day moving average of $2.86.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.